Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB (2019) Pachychoroid disease. Eye (Lond) 33:14–33. https://doi.org/10.1038/s41433-018-0158-4

Article  PubMed  Google Scholar 

Yanagi Y (2020) Pachychoroid disease: a new perspective on exudative maculopathy. Jpn J Ophthalmol 64:323–337. https://doi.org/10.1007/s10384-020-00740-5

Article  PubMed  Google Scholar 

Pang CE, Freund KB (2015) Pachychoroid neovasculopathy. Retina 35:1–9. https://doi.org/10.1097/IAE.0000000000000331

Article  CAS  PubMed  Google Scholar 

Chan WM, Lai TYY, Lai RYK, Tang EWH, Liu DTL, Lam DSC (2008) Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina 28:85–93. https://doi.org/10.1097/IAE.0b013e318156777f

Article  PubMed  Google Scholar 

Fujita K, Imamura Y, Shinoda K, Matsumoto CS, Mizutani Y, Hashizume K, Mizota A, Yuzawa M (2015) One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology 122:555–561. https://doi.org/10.1016/j.ophtha.2014.09.034

Article  PubMed  Google Scholar 

Haga F, Maruko R, Sato C, Kataoka K, Ito Y, Terasaki H (2017) Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: a 3-year follow-up study. PLOS One 12:e0181479. https://doi.org/10.1371/journal.pone.0181479

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lai TYY, Chan WM, Li H, Lai RKL, Liu DTL, Lam DSC (2006) Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol 90:869–874. https://doi.org/10.1136/bjo.2006.090282

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oiwa K, Kataoka K, Maruko R, Ueno S, Ito Y, Terasaki H (2017) Half-dose photodynamic therapy for chronic central serous chorioretinopathy evaluated by focal macular electroretinograms. Jpn J Ophthalmol 61:260–266. https://doi.org/10.1007/s10384-017-0498-9

Article  PubMed  Google Scholar 

Guo J, Tang W, Xu S, Liu W, Xu G (2021) OCTA evaluation of treatment-naïve flat irregular PED (FIPED)-associated CNV in chronic central serous chorioretinopathy before and after half-dose PDT. Eye (Lond) 35:2871–2878. https://doi.org/10.1038/s41433-020-01345-5

Article  CAS  PubMed  Google Scholar 

Hikichi T, Kubo N, Yamauchi M (2021) One-year comparison of anti-vascular endothelial growth factor and half-dose photodynamic therapies for pachychoroid neovasculopathy. Eye (Lond) 35:3367–3375. https://doi.org/10.1038/s41433-021-01418-z

Article  CAS  PubMed  Google Scholar 

Kitajima Y, Maruyama-Inoue M, Ito A, Sato S, Inoue T, Yamane S, Kadonosono K (2020) One-year outcome of combination therapy with intravitreal anti-vascular endothelial growth factor and photodynamic therapy in patients with pachychoroid neovasculopathy. Graefes Arch Clin Exp Ophthalmol 258:1279–1285. https://doi.org/10.1007/s00417-020-04661-4

Article  CAS  PubMed  Google Scholar 

Matsumoto H, Hiroe T, Morimoto M, Mimura K, Ito A, Akiyama H (2018) Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and type 1 neovascular age-related macular degeneration. Jpn J Ophthalmol 62:144–150. https://doi.org/10.1007/s10384-018-0562-0

Article  CAS  PubMed  Google Scholar 

Matsumoto H, Mukai R, Kikuchi Y, Morimoto M, Akiyama H (2020) One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions. Jpn J Ophthalmol 64:203–209. https://doi.org/10.1007/s10384-020-00722-7

Article  CAS  PubMed  Google Scholar 

Miki A, Kusuhara S, Otsuji T, Kawashima Y, Miki K, Imai H, Nakamura M, Tsujikawa A (2021) Photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy. PloS One 16:e0248760. https://doi.org/10.1371/journal.pone.0248760

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tanaka K, Mori R, Wakatsuki Y, Onoe H, Kawamura A, Nakashizuka H (2021) Two-thirds dose photodynamic therapy for pachychoroid neovasculopathy. J Clin Med 10:2168. https://doi.org/10.3390/jcm10102168

Article  PubMed  PubMed Central  Google Scholar 

Smretschnig E, Hagen S, Glittenberg C, Ristl R, Krebs I, Binder S, Ansari-Shahrezaei S (2016) Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy. Eye (Lond) 30:805–811

Article  CAS  PubMed  Google Scholar 

Dansingani KK, Balaratnasingam C, Klufas MA, Sarraf D, Freund KB (2015) Optical coherence tomography angiography of shallow irregular pigment epithelial detachments in pachychoroid spectrum disease. Am J Ophthalmol 160:1243-1254e.2. https://doi.org/10.1016/j.ajo.2015.08.028

Article  PubMed  Google Scholar 

Fung AT, Yannuzzi LA, Freund KB (2012) Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration. Retina 32:1829–1837. https://doi.org/10.1097/IAE.0b013e3182680a66

Article  PubMed  Google Scholar 

Terao N, Koizumi H, Kojima K et al (2018) Association of upregulated angiogenic cytokines with choroidal abnormalities in chronic central serous chorioretinopathy. Invest Ophthalmol Vis Sci 59:5924–5931. https://doi.org/10.1167/iovs.18-25517

Article  CAS  PubMed  Google Scholar 

Guo J, Tang W, Liu W, Chang Q, Xu G (2021) Clinical features of flat irregular pigment epithelial detachment associated with choroidal neovascularization in chronic central serous chorioretinopathy. Retina 41:199–207. https://doi.org/10.1097/IAE.0000000000002791

Article  CAS  PubMed  Google Scholar 

Demirel S, Yanık Ö, Özcan G, Batıoğlu F, Özmert E (2021) A comparative study on the choroidal vascularity index and the determination of cut-off values in the pachychoroid spectrum diseases. Jpn J Ophthalmol 65:482–491. https://doi.org/10.1007/s10384-021-00829-5

Article  CAS  PubMed  Google Scholar 

Wu JS, Chen SN (2019) Optical coherence tomography angiography for diagnosis of choroidal neovascularization in chronic central serous chorioretinopathy after photodynamic therapy. Sci Rep 9:9040. https://doi.org/10.1038/s41598-019-45080-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Erikitola OC, Crosby-Nwaobi R, Lotery AJ, Sivaprasad S (2014) Photodynamic therapy for central serous chorioretinopathy. Eye (Lond) 28:944–957. https://doi.org/10.1038/eye.2014.134

Article  CAS  PubMed  Google Scholar 

Turkcuoglu P, Ilhan N, Kurt J, Aydemir O, Celiker U (2009) The protective role of Visudyne eyeglass against VEGF synthesis after photodynamic therapy with verteporfin. Acta Ophthalmol 87:871–874. https://doi.org/10.1111/j.1755-3768.2008.01368.x

Article  CAS  PubMed  Google Scholar 

Colucciello M (2006) Choroidal neovascularization complicating photodynamic therapy for central serous retinopathy. Retina 26:239–242

Article  PubMed  Google Scholar 

Chen YC, Chen SN (2020) Three-year follow-up of choroidal neovascularisation in eyes of chronic central serous chorioretinopathy. Br J Ophthalmol 104:1561–1566. https://doi.org/10.1136/bjophthalmol-2019-315302

Article  PubMed  Google Scholar 

Hu YC, Chen YL, Chen YC, Chen SN (2021) 3-year follow-up of half-dose verteporfin photodynamic therapy for central serous chorioretinopathy with OCT-angiography detected choroidal neovascularization. Sci Rep 11:13286. https://doi.org/10.1038/s41598-021-92693-z

Article  CAS  PubMed  PubMed Central  Google Scholar